ZhaoYan New Drug Reports 93% Drop in 2024 Non-GAAP Net Profit; Nature Survey Finds 75% of U.S. Scientists Considering Leaving
JOINN
Contract Research Organization (CRO)
Ractigen
Innovative Drug R&D Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
American Scientists Are Having a Hard Time.
On March 28, cuts to U.S. research funding have forced many scientists to rethink their careers. A survey of 1,650 scientists by Nature magazine found that more than 1,200 (about three-quarters of respondents) are considering leaving the U.S. amid the chaos triggered by Trump, with Europe and Canada being the top choices for relocation.
JOINN's performance in 2024 has been unsatisfactory.
On March 28, JOINN released its 2024 financial report. During the reporting period, the company's operating income was 2.018 billion yuan, a year-on-year decrease of 15.07%; the net profit after deducting non-recurring gains and losses was 23.57 million yuan, a year-on-year decrease of 93.02%.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) Hualan Biological Engineering, Inc.'s Net Profit Decreased by 26.57% Year-on-Year in 2024
On March 28, Hualan Biological Engineering, Inc. released its 2024 financial report. During the reporting period, the company achieved operating revenue of 4.379 billion yuan, a year-on-year decrease of 18.02%; net profit attributable to shareholders of the listed company was 1.088 billion yuan, a year-on-year decrease of 26.57%.
2) Minimally Invasive Robotics Reports a Loss of 647 Million Yuan in 2024
On March 27, MicroPort Robot released its 2024 financial report. During the reporting period, the company achieved operating revenue of 257 million yuan, a year-on-year increase of 146%; the loss amounted to 647 million yuan.
3) Heart Medical Technology Reports a Loss of 53.26 Million Yuan in 2024
On March 27, HeartFlow Medical released its 2024 financial report. During the reporting period, the company achieved revenue of 361 million yuan, with a loss of 53.26 million yuan.
4) JOINN's Non-GAAP Net Profit Drops 93.02% in 2024
On March 28, JOINN released its 2024 financial report. During the reporting period, the company's operating income was 2.018 billion yuan, a year-on-year decrease of 15.07%; the net profit after deducting non-recurring gains and losses was 23.57 million yuan, a year-on-year decrease of 93.02%.
/ 02 /
Pharmaceutical News
1) ZMPB-NK006 Injection from US-EU Sai Ao Jin Biotech Receives Clinical Approval
On March 28, according to the CDE official website, the ZMPB-NK006 injection from Meiosai Oujin Biotechnology received clinical approval and is intended for the treatment of advanced or metastatic malignant solid tumors.
2) China National Health ClearTech 3D Mesenchymal Stem Cell Injection Derived from Human Placenta Receives Clinical Approval
On March 28, according to the CDE official website, Guojian Qingke's 3D mesenchymal stem cell injection derived from human placenta obtained clinical approval and is intended for the treatment of acute ischemic stroke.
3) GenScript Biotech's GO306 Recombinant Oncolytic Vaccinia Virus Injection Receives Clinical Approval
On March 28, according to the CDE official website, GO306 Recombinant Oncolytic Vaccinia Virus Injection developed by Jins Biotechnology received clinical approval and is proposed to initiate research for the treatment of solid tumors.
4) Ractigen's RAG-1C Intravitreal Injection Receives Clinical Approval
On March 28, according to the CDE official website, Ractigen's RAG-1C intravitreal injection has been granted clinical approval for the proposed study to treat proliferative vitreoretinopathy.
5) Abogen Biosciences' Freeze-Dried Shingles mRNA Vaccine Receives Clinical Approval
On March 28, according to the CDE official website, Abogen Biosciences' freeze-dried shingles mRNA vaccine received clinical approval and is proposed to conduct research on the prevention and treatment of shingles caused by the varicella-zoster virus.
/ 03 /
Overseas Pharmaceutical News
1) Nature Survey: 75% of Responding Scientists Consider Leaving the United States
On March 28, cuts to U.S. research funding have forced many scientists to reconsider their careers. A survey of 1,650 scientists by Nature magazine found that more than 1,200 (about three-quarters of respondents) are considering leaving the U.S. amid the turmoil triggered by Trump, with Europe and Canada being the top choices for relocation.
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
